Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company’s Scientific Advisory Board
-- Dr. Ashworth Brings Decades of Scientific and Clinical Experience [...]
New Data Underscoring Ability of Leapfrog Bio’s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal
-- Study highlights importance of cancer driver biology in translating [...]
Leapfrog Bio Presents Novel Genetic Sensitizing Mutation Linked to BET Inhibitors and Clinical Development Plans for Lead Product Candidate at the AACR Special Conference in Cancer Research
Leapfrog Bio’s Precision PGx Platform™ discovered a clinically significant link [...]
Leapfrog Bio Announces Publication in Nature PJ Precision Oncology Validating its Proprietary Precision PGx Platform™
Proof-of-concept retrospective analyses performed on currently marketed cancer drugs [...]